Our Services
Medical Information
Helpful Resources
Published on: 8/18/2026
Adult hypophosphatasia (HPP) is often mistaken for osteoarthritis, rheumatoid arthritis, or fibromyalgia because it causes joint pain, stiffness, muscle aches, stress fractures, chondrocalcinosis, and early tooth loss, and because low alkaline phosphatase (ALP) on routine labs is frequently overlooked as unimportant. Key doctor steps include reviewing repeat serum ALP levels against age and sex specific ranges, testing vitamin B6 (pyridoxal 5'-phosphate) and urine phosphoethanolamine, imaging for pseudofractures or metatarsal stress fractures, confirming with ALPL gene testing, and avoiding bisphosphonates, which can worsen HPP. Several important factors affect how quickly this diagnosis is reached, including family history, dental history, and medication history, so see below to understand more.
Because HPP symptoms overlap so heavily with common arthritis, organizing your specific symptoms, fracture history, and dental history before your next appointment can meaningfully change which tests your doctor orders. Take a free, instant, online symptom check to better understand what your pattern of symptoms may suggest and how to navigate next steps with your clinician.
Last reviewed for medical accuracy: 08/18/2026
Adult hypophosphatasia (adult HPP) is a rare, inherited metabolic bone disorder caused by mutations in the gene encoding tissue-nonspecific alkaline phosphatase (TNSALP). Because its symptoms often overlap with common joint and bone conditions—especially arthritis—it can go unrecognized for years. Understanding why this misdiagnosis happens and how doctors work to set things right can help you advocate for an accurate diagnosis and appropriate care.
Many features of adult hypophosphatasia resemble those of osteoarthritis or other joint diseases:
Because these complaints are also typical in degenerative joint disease, adult HPP can be mistaken for common forms of arthritis.
If you or your doctor notice any of the following, adult HPP should enter the differential diagnosis:
Detailed Medical History
Physical Examination
Laboratory Testing
Imaging Studies
Genetic Testing
Multidisciplinary Consultation
When adult HPP is labeled as arthritis, patients may:
Correct identification prevents these pitfalls and opens the door to targeted treatments.
While mild cases may be managed with supportive measures, more serious presentations can benefit from:
Enzyme Replacement Therapy (ERT)
– Asfotase alfa (approved for pediatric and some adult cases)
– Shown to improve bone mineralization and reduce pain
Pain Management and Rehabilitation
– Physical therapy tailored to bone-friendly strengthening
– Low-impact exercise (swimming, cycling)
Dental Care
– Regular checkups to preserve dentition
– Early intervention for loose teeth
Supplementation
– Vitamin D and calcium as indicated (with caution—monitor to avoid hypercalcemia)
Lifestyle Adjustments
– Fall prevention (home safety, assistive devices)
– Balanced diet rich in bone-healthy nutrients
If you’ve been told you have arthritis but experience any of the red flags above, consider these steps:
For a quick, free, online symptom check, try the doctor-approved Ubie Symptom Checker.
Do a free, online symptom check, using the doctor approved Ubie Symptom Checker
Any persistent joint pain, unexplained fractures, or concerning lab values should prompt a discussion with a qualified physician. If you experience symptoms that could be life threatening—such as severe bone pain at rest, acute pseudofracture complications, or sudden dental breakdown—seek medical attention promptly.
Adult hypophosphatasia may be rare, but awareness is growing. By recognizing its unique markers and working closely with your care team, you can avoid misdiagnosis, receive the right treatment, and protect your long-term bone health. Always speak to your doctor about any new or worsening symptoms.
(References)
* Sany J, Rosenberg F, Bataille R, Serre H. [Associated and secondary chondrocalcinosis]. Rev Rhum Mal Osteoartic. 1977 Oct;44(10):565-77. PMID: 337458.
* Rubinstein HM, Shah DM. Pseudogout. Semin Arthritis Rheum. 1972-1973;2(3):259-80. doi: 10.1016/0049-0172(72)90011-x. PMID: 4354552.
* Zwerina J, Dallos T. [Osteoarthritis in hereditary metabolic diseases]. Z Rheumatol. 2010 May;69(3):227-35; quiz 236. doi: 10.1007/s00393-009-0590-8. PMID: 20300760.
* Ma HW. [Rickets-like genetic diseases]. Zhongguo Dang Dai Er Ke Za Zhi. 2013 Nov;15(11):923-7. PMID: 24229581.
* Brandi ML, Khan AA, Rush ET, Ali DS, Al-Alwani H, Almonaei K, Alsarraf F, Bacrot S, Dahir KM, Dandurand K, Deal C, Ferrari SL, Giusti F, Guyatt G, Hatcher E, Ing SW, Javaid MK, Khan S, Kocijan R, Lewiecki EM, Linglart A, M'Hiri I, Marini F, Nunes ME, Rockman-Greenberg C, Seefried L, Simmons JH, Starling SR, Ward LM, Yao L, Brignardello-Petersen R, Roux C. The challenge of hypophosphatasia diagnosis in adults: results from the HPP International Working Group Literature Surveillance. Osteoporos Int. 2024 Mar;35(3):439-449. doi: 10.1007/s00198-023-06859-8. Epub 2023 Nov 20. PMID: 37982856.
* Lei L, Cong R, Ni Y, Cui X, Wang X, Ren H, Wang Z, Liu M, Tu J, Jiang L. Dual-Functional Injectable Hydrogel for Osteoarthritis Treatments. Adv Healthc Mater. 2024 Feb;13(5):e2302551. doi: 10.1002/adhm.202302551. Epub 2023 Nov 30. PMID: 37988224.
* Pascart T, Filippou G, Lioté F, Sirotti S, Jauffret C, Abhishek A. Calcium pyrophosphate deposition disease. Lancet Rheumatol. 2024 Nov;6(11):e791-e804. doi: 10.1016/S2665-9913(24)00122-X. Epub 2024 Jul 29. PMID: 39089298.
* Bertoldo F, Tripepi G, Zaninotto M, Plebani M, Scillitani A, Varenna M, Crotti C, Cipriani C, Pepe J, Minisola S, Pugliese F, Guarnieri V, Baffa V, Torres MO, Zanchetta F, Fusaro M, Rossini M, Brandi ML, Egan CG, Simioni P, Arcidiacono GP, Sella S, Giannini S. Possible role of bone turnover markers in the diagnosis of adult hypophosphatasia. J Bone Miner Res. 2024 Dec 31;40(1):79-86. doi: 10.1093/jbmr/zjae177. PMID: 39498489; PMCID: PMC11983269.
* Wang Q, Feng K, Wan G, Liao W, Jin J, Wang P, Sun X, Wang W, Jiang Q. A ROS-responsive hydrogel encapsulated with matrix metalloproteinase-13 siRNA nanocarriers to attenuate osteoarthritis progression. J Nanobiotechnology. 2025 Jan 16;23(1):18. doi: 10.1186/s12951-024-03046-7. Epub 2025 Jan 16. PMID: 39815302; PMCID: PMC11737235.
* Susin C, Stadler AF, Haas A, Albandar JM. Periodontal Manifestations of Systemic Diseases. J Periodontal Res. 2025 Sep 16. doi: 10.1111/jre.70034. Epub 2025 Sep 16. PMID: 40956006.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.